SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP) Annual Meeting, held November 11-15, 2025 in Boston, MA. Key presentations at the conference highlighted how optical genome mapping (OGM) can enhance the detection of structural variants (SVs) with greater clarity and sensitivity than traditional cytogenetic and molecular techniques. Through platform presentations and poster sessions, multiple researchers emphasized the ...

SAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) offering CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), announced today that the clinical lab fee schedule (CLFS) for 2026 posted by Centers for Medicare & Medicaid Services (CMS) indicates an increase of 47%, from $1263.53 to $1853.22, for the payment for the Category I Current Procedural Terminology (CPT®) code 81195. This code appli ...

Core Viewpoint - Bionano Genomics, Inc. has announced the release of upgraded software versions VIA 7.2 and Solve 3.8.3, along with enhancements to its Stratys Compute server, aimed at improving genomic data analysis and interpretation speed, particularly for hematological malignancies and constitutional genetic disorders [1][2]. Group 1: Software Upgrades - VIA 7.2 automates variant calling, annotation, and interpretation using AI, enhancing the contextualization of variant calls across various data types [1][4]. - Solve 3.8.3 expands its control database of background structural variants (SVs) by 18%, improving sensitivity, specificity, and resolution for SV detection [4][5]. - The upgrades to the Stratys Compute server double the number of cancer samples that can be analyzed per week and expand functionality to include analysis pipelines previously available only on CPU versions [4][5]. Group 2: Company Mission and Offerings - Bionano aims to transform genome analysis through optical genome mapping (OGM) solutions, diagnostic services, and software, catering to basic, translational, and clinical research [3]. - The company provides an industry-leading, platform-agnostic genome analysis software solution and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology [3].

Core Insights - Bionano Laboratories announced the establishment of a new Category I CPT code for optical genome mapping (OGM) in cytogenomic genome-wide analysis, effective January 1, 2026, which is crucial for reimbursement from third-party payers [1][2][3] Group 1: CPT Code Significance - The new CPT code is the second issued for OGM, following code 81195 established in 2024 for hematological malignancies, indicating that OGM has met rigorous Category I standards [2] - The approval of this CPT code is expected to enhance the awareness and utility of OGM in both oncology and clinical genetic testing communities [3] Group 2: Bionano Laboratories' Offerings - Bionano Laboratories provides CLIA-certified laboratory developed tests (LDTs) utilizing OGM technology to detect structural and copy number variations related to genetic disorders [1][4] - The OGM-Dx Postnatal and Prenatal Whole Genome SV tests are designed to detect all classes of structural variants traditionally tested by multiple methods, showcasing the advantages of OGM over legacy methods [3] Group 3: Company Overview - Bionano Genomics aims to transform genome analysis through OGM solutions, diagnostic services, and software, catering to applications across basic, translational, and clinical research [5]